Rat Vascular Endothelial Growth Factor 164AA Recombinant
Category: Recombinant Rat Cytokines$70.00 – $3,500.00
Description
Accession
P16612
Source
Optimized DNA sequence encoding rat VEGF mature chain was expressed in Escherichia Coli.
Molecular weight
Native human rat VEGF is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately kDa. Recombinant rat VEGF is a disulfide-linked homodimeric protein consisting of two amino acid residue subunits, and migrates as an approximately kDa protein under non-reducing conditions and as kDa under reducing conditions in SDS-PAGE.
Purity
>95%, as determined by SDS-PAGE and HPLC
Biological Activity
The ED(50) was determined by the dose-dependent proliferation of Human umbilical vein endothelial cells (HUVEC)was found to be in the less than.0 ng/ml.
Protein Sequence
MNFLLSWVHW TLALLLYLHH AKWSQAAPTT EGEQKAHEVV KFMDVYQRSY CRPIETLVDI FQEYPDEIEY IFKPSCVPLM RCAGCCNDEA LECVPTSESN VTMQIMRIKP HQSQHIGEMS FLQHSRCECR PKKDRTKPEN HCEPCS ERRK HLFVQDPQTC KCSCKNTDSR CKARQL ELNE RTCRCD KPRR
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation
Recombinant rat VEGF was lyophilized from a 0.2 μm filtered PBS solution.
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at2° -8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Biological Process
Biological Process
Molecular function
Molecular function
Molecular function
Methods
Culture of sorted BM Sca-1+/Lin− cells for cardiomyogenic and vasculogenic differentiation and quantitative RT-PCR
- Sorted BM SL cells were plated into a 48-well plate coated with rat vitronectin at a density of 5×105 cells/well and cultured with 2%FBS/EBM-2 supplemented with 10 nM dexamethasone , 0, 1, 10 or 100 ng/mL recombinant human PlGF , and with or without 1 ng/mL mouse VEGF (ocky , ) for 7 days.
- Total RNA was then obtained using RNeasy Mini kit according to the manufacturer's instructions.
Media preparation
- Vascular Medium (VM) consisted of endothelial basal medium-2 , 6% FBS, 1% penicillin/streptomycin, 10 ng/mL vascular endothelial growth factor-165 (VEGF), 1 ng/ml FGF-2, and 1 µg/mL L-ascorbic acid-2-phosphate .
- For monolayer osteogenic differentiation experiments, Control consisted of low glucose DMEM , 6% FBS, and 1% penicillin/streptomycin consisted of Control plus 10 mM β-glycerophosphate and 50 µM L-ascorbic acid-2-phosphate.
- To support both vascular growth and osteogenic differentiation, OM was further supplemented with 10 /ml VEGF and 1 ng/ml FGF-2 for studies within fibrin gels and PCL scaffolds.
